Continuous intravenous infusion of insulin to girls with hereditary tall growth and secretion of human growth hormone, prior to and during Deposiston treatment
Richter, J.; Heine, W.; Rudolf, K.; Uhlmann, M.
Zentralblatt für Gynakologie 102(19): 1117-1120
1980
ISSN/ISBN: 0044-4197 PMID: 7008461 Document Number: 156615
Continuous intravenous insulin infusion tests, accompanied by growth hormone determination, were applied to 40 tall girls whose final heights were predicted to be in excess of 181 cm. The girls, ages 9 1/2 to 14 years 1 month were all premenstrual. Tests were conducted prior to and following at least 1 year of Deposiston therapy (estrogen gestagen). Truly effective inhibition of growth (7.4 + or - 0.6 cm) was seen only in 5 girls ages 9 years 10 months and 11 years in whom basal secretion of HGH was lower than the rest of the group. Their stimulation reaction was fully retained. Secretion of somatotropic hormone of the other girls remained unaffected prior to and following treatment. The weekly estrogen dose of 4 mg was relatively low when compared to administrations reported by other authors but it seemed justified by the average reduction in expected final body height obtained for the subjects reviewed (5.4 + or - 2.0 cm). (Author's modified)